JP2008509928A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509928A5
JP2008509928A5 JP2007525838A JP2007525838A JP2008509928A5 JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5 JP 2007525838 A JP2007525838 A JP 2007525838A JP 2007525838 A JP2007525838 A JP 2007525838A JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5
Authority
JP
Japan
Prior art keywords
use according
methylene
tetraazacyclotetradecanyl
phenylenebis
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/028783 external-priority patent/WO2006020891A2/en
Publication of JP2008509928A publication Critical patent/JP2008509928A/ja
Publication of JP2008509928A5 publication Critical patent/JP2008509928A5/ja
Withdrawn legal-status Critical Current

Links

JP2007525838A 2004-08-13 2005-08-11 前駆／幹細胞を動員するためのケモカインの組み合わせ Withdrawn JP2008509928A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13
PCT/US2005/028783 WO2006020891A2 (en) 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
JP2008509928A JP2008509928A (ja) 2008-04-03
JP2008509928A5 true JP2008509928A5 (https=) 2008-10-09

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525838A Withdrawn JP2008509928A (ja) 2004-08-13 2005-08-11 前駆／幹細胞を動員するためのケモカインの組み合わせ

Country Status (9)

Country Link
US (1) US20060035829A1 (https=)
EP (1) EP1796716A4 (https=)
JP (1) JP2008509928A (https=)
CN (1) CN101094684A (https=)
AU (1) AU2005272653A1 (https=)
BR (1) BRPI0514343A (https=)
CA (1) CA2577046A1 (https=)
TW (1) TW200608991A (https=)
WO (1) WO2006020891A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CA2619828A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
NZ702415A (en) * 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
JP2016516672A (ja) * 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
JP2019507596A (ja) * 2016-02-26 2019-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 生着性の高い造血幹細胞
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
MX392743B (es) 2017-04-12 2025-03-12 Magenta Therapeutics Inc Antagonistas del receptor de hidrocarburo de arilo y sus usos.
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
EP3735412B1 (en) 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69433301T2 (de) * 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
CA2178902A1 (en) * 1993-12-14 1995-06-22 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DE60042030D1 (de) * 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU2002211393B2 (en) * 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
EP1385865A4 (en) * 2001-04-03 2005-05-25 Applera Corp ISOLATED HUMAN KINASEPROTEINS, NUCLEIC ACID MOLECULES CODING FOR HUMAN KINASEPROTEINS AND THEIR USES
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
WO2003048345A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) * 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2008509928A5 (https=)
US12037321B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators
CA2455559A1 (en) Methods to mobilize progenitor/stem cells
ES2983582T3 (es) Composiciones bioortogonales
JP2014513727A5 (https=)
JP2008528658A5 (https=)
JP2017533922A5 (https=)
JP2008195730A5 (https=)
JP2019089794A (ja) 治療薬を局所的送達するための化学構造
JP2014528467A5 (https=)
JP2017511360A5 (https=)
JP2011006428A5 (https=)
CA2361587A1 (en) Methods and compositions to enhance white blood cell count
RU2010113982A (ru) Применение пептида в качестве терапевтического средства
JP2022095872A5 (https=)
US20240158445A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
CN101495115A (zh) 组合治疗
AU2016202594B2 (en) Scheme for administering N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)­benzofuran-2-ylcarbonylamino]ethoxy}benzamide
RU2014124171A (ru) Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе
MY145838A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
JP2005527479A5 (https=)
CN101175490B (zh) 循环障碍改善剂
JP2008520682A (ja) ヒストンデアセチラーゼ阻害剤およびその使用方法
EP1345604B1 (en) Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer
WO2008113095A1 (en) Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)